Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
Article excerpt
NEW BRUNSWICK, N.J., Nov. 8, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ ) today announced promising first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to drive the body's immune response against advanced prostate cancer. At the recommended regimen, 73 percent (11 of 15 patients) achieved reductions of at least 50 percent in prostate-specific antigen (PSA), a marker used to monitor prostate cancer activity, including 47 percent (7 of 15 patients) who achieved reductions of at least 90 percent. Results were presented in a late-breaking oral session at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting (Abstract #1175). 1 The combination represents the first dual-tumor-antigen-targeted bispecific antibody regimen clinically evaluated in prostate cancer, targeting kallikrein-related peptidase 2 (KLK2) and prostate-specific membrane antigen (PSMA) through complementary T-cell signals designed to activate and enhance the function of immune cells against cancer. In the study, deep and sustained PSA responses were observed, with all seven patients who achieved reductions of at least 90 percent remaining on treatment for more than six months without disease progression. No Grade 3 or higher treatment-related adverse events were reported in this early analysis. 1 A...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
Extracted from this sentence
With this combination now in Phase 3 development, we are building on the early promise of this approach as we work to bring new treatment options to patients with advanced disease.
